Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Khanh Bao Tran(Praevium Research (United States)), Peter R. Shepherd(University of Auckland)
BMC Cancer
February 6, 2021
Cited by 36


Related Papers